Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
NCT00683410
Last updated date
ABOUT THIS STUDY
To collect post-marketing information on the safety of Prevenar in Filipino patients
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Vaccines, Pneumococcal Conjugate Vaccine
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- All patients from the study center who received or will receive at least one dose of Prevenar according to the approved product indication.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Previously discontinued Prevenar therapy due to safety concerns.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Vaccines, Pneumococcal Conjugate VaccineStudy Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan
NCT00688870
- Taipei,
- Taoyuan Hsien,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Vaccines, Pneumococcal Conjugate VaccineStudy to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
NCT00269672
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Vaccines, Pneumococcal Conjugate VaccineStudy Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
NCT00500357
- Amanzimtoti,
- Bishop Lavis,
- Bloemfontein,
- Brits,
- Cape Town,
- Cape Town,
- Lenasia,
- Paarl,
- Parow,
- Parys,
- Pretoria,
- Pretoria,
- Pretoria,
- Pretoria,
- Scottburgh South,
- Vanderbijlpark,
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Vaccines, Pneumococcal Conjugate VaccinePost-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
NCT00683410
- Muntinlupa City,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent) | |||
| Official Title | A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Pneumococcal Conjugate Vaccine, 7-valent (Prevenar) 0.5 mL by Intramuscular Injection | |||
| Brief Summary | To collect post-marketing information on the safety of Prevenar in Filipino patients | |||
| Detailed Description | Not Provided | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Case-Only Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | Primary Care | |||
| Condition | Vaccines, Pneumococcal Conjugate Vaccine | |||
| Intervention | Biological: Pneumococcal Conjugate Vaccine, 7-valent (Prevenar) | |||
| Study Groups/Cohorts | 1
Intervention: Biological: Pneumococcal Conjugate Vaccine, 7-valent (Prevenar) | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 3366 | |||
| Original Estimated Enrollment | 3000 | |||
| Actual Study Completion Date | October 2009 | |||
| Actual Primary Completion Date | October 2009 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | Child, Adult, Older Adult | |||
| Accepts Healthy Volunteers | Yes | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Philippines | |||
| Removed Location Countries | United States | |||
| Administrative Information | ||||
| NCT Number | NCT00683410 | |||
| Other Study ID Numbers | 0887X-102339 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth | |||
| Study Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Verification Date | October 2010 | |||